tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Edwards Lifesciences sees FY25 adjusted EPS at high end of $2.40-$2.50

Consensus $2.47. Raises FY25 revenue view to $5.9B-$6.1B from $5.7B-$6.1B, consensus $5.9B.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1